Compare Schlumberger NV (SLB) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs Zoetis Inc — how do they compare? Schlumberger NV trades at $48.95 (market cap $72.69B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Schlumberger NV is far larger — about 2.4× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Schlumberger NV for 99 Days and Zoetis Inc for 70 Days on average.
| SLB | ZTS | |
|---|---|---|
Market Cap | $72.69B | $30.20B |
Volume | 16,228,451 | 6,175,327 |
Sector | Energy | Health |
52-Week High | $60.10 | $147.53 |
52-Week Low | $31.72 | $69.09 |
Typical Hold Time | 99 Days | 70 Days |
Enterprise Value | $81.42B | $37.76B |
Dividend Yield | 2.41% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLB trades at $48.98, up 2.13% today, with a bearish technical signal despite recent earnings beats. The company secured major contracts in Oman and Mozambique, expanding its international footprint. Revenue declined slightly to $35.71B in 2025, with net income margin at 8.53%. Analyst consensus remains strongly bullish with 85% buy ratings and a $64.58 price target, representing 32% upside potential.
SLB faces near-term headwinds from declining profit margins and bearish technical indicators, but strong contract wins and analyst optimism suggest long-term growth potential. Key risks include oil price volatility and execution challenges in new markets. The stock offers value at current levels for investors with a medium-to-long-term horizon.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
